Menu
Immuno Oncology Europe
Immuno Oncology Europe
Immuno-Oncology Summit Europe
-欧洲癌症免疫高峰会-
日期:2017年3月20-24日
地点:英国伦敦,Hilton Canary Wharf

大会议程

Novel Approaches for Cancer   Immunomodulatory Approaches  Combination Immunotherapy

短期会议

3月21日 18:30-21:30

Dinner SC1:
New Directions in Cancer Immunotherapy (癌免疫疗法新方向)

Dinner SC2:
CAR T and TCR Manufacturing Challenges to Anticipate and Overcome: Focus on How, Where, and Cost Factors (CAR-T及TCR制造相关课题预测及克服:方法、场所、费用要因)
 

Featured Presenters

Roy BaynesRoy D. Baynes, M.D., Ph.D.
Senior Vice President and Head, Global Clinical Development, CMO, Merck Sharp & Dohme

Zelig EshharZelig Eshhar, Ph.D.
Chair, Cancer Immunotherapy, Research and Development, Sourasky Medical Center, Tel Aviv

David FeltquateDavid Feltquate, M.D., Ph.D.
Vice President, Oncology Development, Bristol-Myers Squibb

Dario NeriDario Neri, Ph.D.
Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH), Zurich

Andy_SewellAndrew Sewell, Ph.D.
Professor, Institute of Infection & Immunity, Cardiff University School of Medicine

Robert WilkinsonRobert W. Wilkinson, Ph.D.
Director, Oncology Research, MedImmune Ltd.

 


关于本高峰会

承接上届高峰会的成功经验,Immuno-Oncology Summit Europe在2017年也将继续举行。本届高峰会将跟2016年一样,在伦敦的中心地带举行,是世界各国研究人员及业界相关人士不可错过的重要活动。

本高峰会为期一周,将针对最新研究成果展开热烈的讨论。在癌症治疗新方法的议程中,将聚焦于包含CAR-T技术在内的T细胞及受体、双特异性抗体、临床前模型、标的及先导化合物的选定等主题。免疫调节疗法议程中,将深入讨论检查点抑制剂、活化受体的关联、NK、巨噬体及树状细胞的活化、Fc工程技术、细胞激素疗法、溶瘤疫苗等主题在各领域研究的进展状况。此外,在并用免疫疗法的议程中,除了并用疗法的设计与策略相关演讲之外,也将介绍临床前研究与临床研究的最新情报。


上届高峰会的参加者之声

"Very stimulatory meeting in an exciting field. Great mix of complementary presentations."

Kerry Chester, Ph.D., Professor, UCL Cancer Institute

"I believe you managed to collate an excellent mix of speakers spanning the most critical aspects of immune oncology, providing an informal forum for discussions between leaders in the field and new investigators coming from both academia and industry."

Björn Frendéus, Ph.D., Chief Scientific Officer, BioInvent International AB

"The content of the meeting was highly relevant and up to date."

Khaterech Ahmadi, Executive Director, MSD-Merck

"The meeting was ideal in terms of size and content. I really enjoyed the conference. It was very insightful and great quality of research was presented."

Sujiet Puthenveetil, Ph.D., Principal Scientist, Medicinal Chemistry, Pfizer, Inc.

Choose your language
Chinese
Japanese
Korean
English

Catalog



免费电子邮件通知服务
免费电子邮件通知服务